JAMES POOL to Adrenergic alpha-Antagonists
This is a "connection" page, showing publications JAMES POOL has written about Adrenergic alpha-Antagonists.
Connection Strength
0.895
-
Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia. Int Urol Nephrol. 2001; 33(3):407-12.
Score: 0.176
-
Alpha adrenoceptor blockade in the treatment of benign prostatic hyperplasia: past, present and future. Br J Urol. 1997 Oct; 80(4):521-32.
Score: 0.141
-
Doxazosin: a new approach to hypertension and benign prostatic hyperplasia. Br J Clin Pract. 1996 Apr-May; 50(3):154-63.
Score: 0.127
-
Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J. 1991 Sep; 122(3 Pt 2):926-31.
Score: 0.092
-
Alpha 1-adrenoreceptor blockade and the molecular basis of lipid metabolism alterations. J Hum Hypertens. 1990 Oct; 4 Suppl 3:23-33.
Score: 0.087
-
Review of the effects of doxazosin, a new selective alpha 1-adrenergic inhibitor, on lipoproteins in patients with essential hypertension. Am J Med. 1989 Aug 16; 87(2A):57S-61S.
Score: 0.080
-
Terazosin (Hytrin): cumulative experience of clinical trials in the USA for the treatment of mild to moderate essential hypertension. Br J Clin Pract Suppl. 1987 Dec; 54:9-14.
Score: 0.071
-
Plasma lipid lowering effects of doxazosin, a new selective alpha1 adrenergic inhibitor for systemic hypertension. Am J Cardiol. 1987 May 29; 59(14):46G-50G.
Score: 0.069
-
Role of the sympathetic nervous system in hypertension and benign prostatic hyperplasia. Br J Clin Pract Suppl. 1994 May; 74:13-7.
Score: 0.028
-
Antihypertensive and metabolic effects of concomitant administration of terazosin and methyclothiazide for the treatment of essential hypertension. J Clin Pharmacol. 1992 Apr; 32(4):351-9.
Score: 0.024